1. Home
  2. HOWL vs TLSA Comparison

HOWL vs TLSA Comparison

Compare HOWL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.60

Market Cap

182.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOWL
TLSA
Founded
2017
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.5M
182.7M
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
HOWL
TLSA
Price
$0.65
$1.60
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$6.50
N/A
AVG Volume (30 Days)
923.1K
385.6K
Earning Date
11-04-2025
05-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$0.63
52 Week High
$2.38
$2.60

Technical Indicators

Market Signals
Indicator
HOWL
TLSA
Relative Strength Index (RSI) 33.88 48.90
Support Level $0.60 $1.47
Resistance Level $0.74 $1.62
Average True Range (ATR) 0.08 0.16
MACD -0.01 0.01
Stochastic Oscillator 13.27 58.82

Price Performance

Historical Comparison
HOWL
TLSA

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: